Jubilant Lifesciences has got the USFDA’s final approval for its generic drug.
The US drug regulator has provided its final approval to Jubilant’s generic Levetiracetam injection which is used in the treatment of epilepsy, in the American market.
Jubilant Lifescience shares surged 6 percent on Monday after the firm has got final approval from USFDA for its generic drug.
